Dnamethylation status of key cell-cycle regulators such as CDKNA2/P16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors

Clinical Cancer Research

Volumn 20, Issue 24, 2014, Pages 6357-6366

  Klajic, Jovana ^a,b,c   Busato, Florence ^d   Edvardsen, Hege ^c   Touleimat, Nizar ^d   Fleischer, Thomas ^b,c   Bukholm, Ida ^a,e   Børresen Dale, Anne Lise ^b,c   Lønning, Per Eystein ^f,g   Tost, Jöorg ^d   Kristensen, Vessela N ^a,b,c,e  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d CENTRE NATIONAL DE GÉNOTYPAGE   (France)

^e UNIVERSITY OF OSLO   (Norway)

^f UNIVERSITY OF BERGEN   (Norway)

^g HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A1; CYCLIN D2; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOXORUBICIN; FLUOROURACIL; MITOMYCIN; SOMATOMEDIN BINDING PROTEIN 3; TRANSCRIPTION FACTOR FOXC1; ANTINEOPLASTIC AGENT; CCNA1 PROTEIN, HUMAN; CELL CYCLE PROTEIN; PROTEIN P53;

ALU SEQUENCE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CCNA1 GENE; CCND2 GENE; CDKN2A GENE; COHORT ANALYSIS; CONTROLLED STUDY; DNA METHYLATION; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; FOXC1 GENE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IGFBP3 GENE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PROMOTER REGION; TUMOR SUPPRESSOR GENE; BREAST NEOPLASMS; CANCER STAGING; FEMALE; GENE EXPRESSION PROFILING; GENETICS; MUTATION; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; COHORT STUDIES; CYCLIN A1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DOXORUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84919666204     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0297     Document Type: Article

References (32)

1. Lonning PE. Molecular basis for therapy resistance. Mol Oncol 2010;4:284-300.
2. Kaufmann M, von MG, Bear HD, Buzdar A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007;18: 1927-34.
3. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5-23.
4. Lonning PE, Knappskog S. Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. Oncogene 2013;32:5315-30.
5. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge O, Haugen DF, et al. In fluence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001;61:2505-12.
6. Geisler S, Borresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, et al. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003;9:5582-8.
7. Jovanovic J, Ronneberg JA, Tost J, Kristensen V. The epigenetics of breast cancer. Mol Oncol 2010;4:242-54.
8. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
9. Sandhu R, Rivenbark AG, Coleman WB. Enhancement of chemotherapeutic ef fi cacy in hypermethylator breast cancer cells through targeted and pharmacologic inhibition of DNMT3b. Breast Cancer Res Treat 2012;131:385-99.
10. Boettcher M, Kischkel F, Hoheisel JD. High-definitionDNAmethylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistance. PLoS ONE 2010;5:e11002.
11. Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977;35:292-8.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 2000;92:205-16.
13. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc 2007;2:2265-75.
14. Ingenuity® Systems. Ingenuity Pathway Analysis. [Accessed July 16 2014]. Available from: http://www.ingenuity.com/products/ipa.
15. Buchholz TA, Stivers DN, Stec J, Ayers M, Clark E, Bolt A, et al. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 2002;8:461-8.
16. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profi ling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9.
17. Lonning PE. Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance. Trends Mol Med 2004;10:113-8.
18. Emens LA, Machiels JP, Reilly RT, Jaffee EM. Chemotherapy: friend or foe to cancer vaccines? Curr Opin Mol Ther 2001;3:77-84.
19. Lake RA, Robinson BW. Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 2005;5:397-405.
20. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54-61.
21. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancerchemotherapy and radiotherapy. NatMed2007;13:1050-9.
22. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005;65:5009-14.
23. Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009;69:3105-13.
24. Hua D, Liu MY, Cheng ZD, Qin XJ, Zhang HM, Chen Y, et al. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol 2009;46:2876-84.
25. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-30.
26. Klajic J, Fleischer T, Dejeux E, Edvardsen H, Warnberg F, Bukholm I, et al. Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer 2013;13:456.
27. Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, et al. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res 2001;61: 2782-7.
28. Starlard-Davenport A, Kutanzi K, Tryndyak V, Word B, Lyn-Cook B. Restoration of the methylation status of hypermethylated gene promoters by microRNA-29b in human breast cancer: a novel epigenetic therapeutic approach. J Carcinog 2013;12:15.
29. Leonova KI, Brodsky L, Lipchick B, Pal M, Novototskaya L, Chenchik AA, et al. p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc Natl Acad Sci U S A 2013;110:E89-E98.
30. Ting DT, Lipson D, Paul S, Brannigan BW, Akhavanfard S, Coffman EJ, et al. Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science 2011;331:593-6.
31. Li TH, Kim C, Rubin CM, Schmid CW. K562 cells implicate increased chromatin accessibility in Alu transcriptional activation. Nucleic Acids Res 2000;28:3031-9.
32. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jonsson G, Olsson H, et al. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 2010;12: R36.